Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore, a bioelectronic medicine company, has appointed Sylvester "Sly" Steele as Vice President and General Manager of its newly established Government Channels Business Unit. With over 20 years of experience in the U.S. Navy, Steele will focus on expanding the reach of gammaCore Sapphire non-invasive vagus nerve stimulation therapy, particularly within the Veterans Administration and Department of Defense. The company aims to leverage his skills to drive growth and create new revenue opportunities in government sectors.
electroCore (Nasdaq: ECOR) anticipates Q3 2020 revenue will surpass $1 million, marking over a 35% increase sequentially and over 50% from Q3 2019. The company reported an operating cash burn of approximately $4.1 million, while raising $11.2 million through an existing stock purchase agreement. The Department of Veterans Affairs has agreed to sponsor a study of gammaCore Sapphire for veterans with traumatic brain injury and PTSD. Despite challenges due to COVID-19, the company is well-positioned for future growth.
electroCore, Inc. (NASDAQ: ECOR) has partnered with UpScript, LLC to provide exclusive telehealth services for its gammaCore Sapphire™ CV device, aimed at treating COVID-19 patients experiencing asthma-related breathing issues. Patients can access consultations and prescriptions via UpScript’s platform. This initiative comes under the FDA's Emergency Use Authorization (EUA), permitting the device's home use for eligible patients. The collaboration aims to streamline access to this therapy, enhancing patient care during the pandemic.
electroCore, a bioelectronic medicine company, will have CEO Dan Goldberger participate in a fireside chat at the JMP Securities MedTech Bio Summit on October 1, 2020, at 2:00 PM ET. This virtual event will be accessible via a live webcast, furthering the company's outreach and engagement with investors.
electroCore focuses on non-invasive vagus nerve stimulation therapies, currently targeting migraine and cluster headache treatments. For more details, visit www.electrocore.com.
electroCore, Inc. (Nasdaq: ECOR) announced its participation in the HC Wainwright Virtual 22nd Annual Global Investment Conference from September 14-16, 2020. The company will present on September 16, 2020, from 1:30-1:50 PM EDT. Interested parties can access a live webcast through the Investors section of the company's website. electroCore specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapy for conditions such as cluster headaches and migraines.
electroCore, Inc. (Nasdaq: ECOR) announced the publication of a study in Brain Stimulation demonstrating that non-invasive vagal nerve stimulation (nVNS) significantly decreases brain activity related to trauma in patients without PTSD. Conducted on 19 subjects, the study showed that nVNS led to critical improvements, highlighting its potential utility in treating psychiatric disorders like PTSD. The treatment is a promising alternative to existing therapies, which often have limitations. The research was sponsored by DARPA and further studies are anticipated.
electroCore (NASDAQ:ECOR) will present at the LD 500 investor conference on September 3rd at 6:20 AM PST / 9:20 AM EST, showcasing its unique bioelectronic medicine solutions. CEO Dan Goldberger will address the audience during this virtual event, which runs from September 1st to 4th. The conference provides a platform for engaging with investors interested in microcap companies. electroCore focuses on non-invasive vagus nerve stimulation, targeting conditions like migraine and cluster headaches.
electroCore (Nasdaq: ECOR) announced a Voluntary ex-ante Transparency Tender Notice published by NHS England, naming it the sole supplier of non-invasive vagus nerve stimulation therapy. This contract provides additional funding for gammaCore therapy to treat cluster headaches, running from October 1, 2020, to March 31, 2021, with a potential 3-year extension. Iain Strickland highlighted NHS England's commitment to providing cost-effective treatments. gammaCore is the only medical technology recommended by NICE for cluster headaches, fulfilling an essential patient need.
electroCore, a bioelectronic medicine company, received Emergency Use Authorization for gammaCore Sapphire CV to treat asthma exacerbations in COVID-19 patients. The company reported net sales of $753,000 for Q2 2020, slightly exceeding guidance, and reduced net cash burn to $5.2 million. Operating expenses fell by 50% year-over-year. The company strengthened its balance sheet by raising $10.3 million post-quarter, leading to pro forma cash of $29.2 million. Key revenue channels showed signs of recovery, with total operating expenses significantly reduced from $12.7 million in Q2 2019.
electroCore, Inc. (Nasdaq: ECOR) will announce its financial results for the second quarter ended June 30, 2020, on August 13, 2020, after market close. A conference call will take place at 4:30 PM Eastern Time to discuss the results and address questions. The company, focused on bioelectronic medicine, aims to enhance patient outcomes with its non-invasive vagus nerve stimulation therapy targeting conditions like cluster headaches and migraines.